Sexualized drug use and chemsex: a case-based workshop

Cara Borelli, DO (she/her/hers) – Yale School of Medicine , CT Chun M. Tong, MD (he/him/his) – Christian Health, New Jersey Alyssa Cheng, DO (she/her/hers) - Yale School of Medicine, CT Newman Kessler, MD (he/him/his) – Mount Sinai (non-presenting), NY Jenna Butner, MD, MPH, FASAM – Yale School of Medicine (non-presenting), CT



Disclosure Information

Presenter 1: Cara Borelli, DO

- No Disclosures
- Presenter 2: Chun Tong, MD
 - No Disclosures
- Presenter 3: Alyssa Cheng, DO
 - No Disclosures
- Presenter 3: Newman Kessler, MD
 - No Disclosures
- Presenter 4: Jenna Butner, MD, MPH, FASAM
 - No Disclosures



Learning Objectives

After participating in the session, attendees should be able to:

- Describe the current trends sexualized drug use in the LGBTQ population.
- Employ evidence-based substance use treatment in a culturally-competent manner to LGBTQ patients seeking treatment, including the overlap with mental health and medical care.
- Apply harm reduction strategies to chemsex and sexualized drug use.



Background

-Sexualized drug use refers to sexual activity while using psychoactive drugs to enhance the sexual experience, and it is often associated with gay and bisexual men -"Chemsex" can be used broadly but typically refers to the use of gamma-hydroxybutyrate (GHB), methamphetamine, or mephedrone

Sources: Giorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E, Busardò FP. When "Chems" Meet Sex: A Rising Phenomenon Called "ChemSex". Curr Neuropharmacol. 2017;15(5):762-770. doi: 10.2174/1570159X15666161117151148. PMID: 27855594; PMCID: PMC5771052.



Substance use rates in the LGBTQ community

- Individuals in the LGBTQ have higher rates of mental health disorders and substance use disorder:
 - E.g., gay men were 2-3 times more likely to have had a major depressive episode in the past year than straight men
 - Approximately 1/4 of lesbian women had a substance use disorder in the past year
 - The LGBTQ community is not a monolithic population; individualized research required

Mental Health Services Administration. (2023). Lesbian, gay, and bisexual behavioral health: Results from the 2021 and 2022 National Surveys on Drug Use and Health (SAMHSA Publication No. PEP23-07-01-001). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.

Stress Theory

• Minority stress theory: highlights unique stressors faced by sexual minorities (Ilan Meyer)

- Distal stressors
 - Overt discrimination and harassment
 - Societal stigma
- Proximal stressors/stress reactions
 - Internalized homophobia and stigma
 - Identity concealment
 - Rejection sensitivity
- Gay community stress theory: expands on minority stress-theory to focus on unique stressors originating within the gay community (Soulliard et al)
 - Focus on social status associated with appearance
 - Emphasis on a muscular body type as a masculine ideal
 - Scrutiny and objectification by other gay men who may be potential sexual partners



Background: treatment

-Addressing substance use in the LGBTQ population should include assessment and referral if applicable for mental health co-morbidities.

-Offering relevant medical management is critical, including withdrawal treatment and medications for substance use disorders when applicable.

-Harm reduction can take many different forms in sexualized drug use including novel initiatives in the information age.

-Another emerging treatment modality is LGBTQ-specialized treatment programs for substance use, which were found to have better outcomes compared to non-specialized treatment programs.



Sources: Senreich E. Are specialized LGBT program components helpful for gay and bisexual men in substance abuse treatment? Subst Use Misuse. 2010;45(7-8):1077-1096. doi:10.3109/10826080903483855. Cochran BN, Peavy KM, Robohm JS. Do specialized services exist for LGBT individuals seeking treatment for substance misuse? A study of available treatment programs. Subst Use Misuse. 2007;42(1):161-176. doi:10.1080/10826080601094207.

Methamphetamine use in the information age

Chun Tong, MD



Addiction Psychiatry

EDITION SIXTH The American Psychiatric Association Publishing TEXTBOOK of **SUBSTANCE USE DISORDER** TREATMENT EDITED BY Kathleen T. Brady, M.D., Ph.D. Frances R. Levin, M.D. Marc Galanter, M.D. Herbert D. Kleber, M.D.



LUST, MEN AND METH

A GAY MAN'S GUIDE TO SEX AND RECOVERY

DAVID FAWCETT, PhD

Foreword by Mark S. King



Pocket Guide to LGBTQ Mental Health Understanding the Spectrum of

Gender and Sexuality

Petros Levounis, M.D., M.A. Eric Yarbrough, M.D.

Adrian Jacques H. Ambrose, M.D., M.P.H. Ahmad A. Mohammad, M.D. Angeliki Pesiridou, M.D. Daena L. Petersen, M.D., M.P.H., M.A. E.K. Breitkopf, M.A. Mark Joseph Messih, M.D., M.Sc. Mary E. Barber, M.D. Murat Altinay, M.D. Nix Zelin, M.D. Sam Marcus, M.A. Sarah Noble, D.O. Selale Gunal Serena M. Chang, M.D. Victoria Formosa, L.C.S.W. Eric Yarbrough, M.D. Petros Levounis, M.D., M.A.



Addiction in LGBTQ Communities and Crystal Methamphetamine

> Petros Levounis, MD, MA Professor and Chair, Department of Psychiatry, and Associate Dean for Professional Development Rutgers New Jersey Medical School

Rush University Department of Psychiatry and Behavioral Sciences Section of Addiction Psychiatry Chicago, Illinois, via Zoom September 17, 2020





A 59-year-old, White/Caucasian, homosexual cis-gender man with a history of stimulant use disorder (crystal meth) and substance-induced mood disorder, present to the Addiction Institute (AI) outpatient clinic for follow up. The patient reports a gradual reduction of crystal meth use since he started follow up at Crystal Clear, and was referred to the clinic by his therapist for additional psychopharmacological intervention to help reduce his use further.





He responded well to **Mirtazapine 30 mg PO QDay** (Coffin et al. 2020, Siegfried et al. 2020), coupled with various behavioral and social modification (emotional support animal, ESA). The patient reports **continue reduction in use**, down to about or less than once a month, and he attributes his improvement to medication and ESA. However, he still have trouble achieving total abstinence (his treatment goal).



Coffin PO, Santos G, Hern J, et al. Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial. JAMA Psychiatry. 2020;77(3):246–255. doi:10.1001/jamapsychiatry.2019.3655 Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review. CNS Drugs. 2020 Apr;34(4):337-365. doi: 10.1007/s40263-020-00711-x. PMID: 32185696; PMCID: PMC7125061.



Upon reviewing the last few uses in 2023, the patient report a pattern of downloading dating app/hookup app i.e. Grindr as a mean to look for user for intimacy & drug use. In the past, he would look for sex & users in bathhouses and through texting, and gradually it is replaced by mobile apps. He found himself deleting and re-downloading whenever he feels lonely or have craving.

What else would you want to know? What would you recommend?



NEWS POLITICS U.S. NEWS TITLE 42 BUSINESS TECH WORLD HEALTH CULTURE & TRENDS NBC NEWS TIPLINE • WATCH NOW

OUT HEALTH AND WELLNESS

Sex and drugs: Popular gay dating app allows users to find more than a date

Despite Grindr's past efforts to address the selling and promoting of drugs on its app, those who use it say there's still a robust market for illicit substances.





ын ат&т रू 5:37 РМ	f 🛛 🕏 69% 💼 +	III AT&T 🗢	9:57 PM	(1)	و 37% 🔳
ParTlyKloudy 25 ● Online now ◆ 686 m away		<			
Can geT you whaT you looking for. Only contact me for business Height 178 cm		42o‱&@@4Sale 22			
Weight 70 kg		 Online now 9 km away 		\mathfrak{O}	$\overline{\nabla}$
Body Type Slim		Hi meetina			
Looking for Networking					











Apps use & drug use

Phillips et al. 2014 – MSM that uses GSN app users reported a significantly higher use of crystal meth, poppers, and painkillers in the previous 12 months compared with non-users

Fansher and Eckinger 2020 - Tinder users (in a sample of US college students under age of 30) were more likely to have consumed drugs during the past three months than Tinder non-users

Erevik et al. 2020 - Tinder users (in a sample of single Norwegian students) were more likely to have consumed drugs during the past three months than Tinder nonusers.

(?) The term "User" - is not universally defined.



- Phillips, Gregory, Manya Magnus, Irene Kuo, Anthony Rawls, James Peterson, Yujiang Jia, Jenevieve Opoku, and Alan E. Greenberg.2014. Use of Geosocial Networking (GSN) Mobile Phone Applications to Find Men for Sex by Men Who Have Sex with Men (MSM) in Washington, DC. AIDS and Behavior 18: 1630–37.
- Fansher, Ashley K., and Sara Eckinger. 2020. Tinder Tales: An Exploratory Study of Online Dating Users and Their Most Interesting Stories. Deviant Behavior, 1–15.
- Erevik, Eilin K., Joakim H. Kristensen, Torbjørn Torsheim, Øystein Vedaa, and Ståle Pallesen. 2020. Tinder Use and Romantic Relationship Formations: A Large-Scale Longitudinal Study. Frontiers in Psychology 11.

Apps use & drug use





Article

The Relationship between Drug Consumption and Dating App Use: Results from an Italian Survey

Luca Flesia ^{1,*}, Valentina Fietta ², Carlo Foresta ¹, and Merylin Monaro ²

1278 Italian respondents completed an online ad hoc questionnaire

- Using dating apps accounted for higher odds of cannabis use; however, people who intensely used the apps were less likely to consume marijuana
- Dating app use was not associated with the consumption of other drugs.



Apps use & drug use





Article

The Relationship between Drug Consumption and Dating App Use: Results from an Italian Survey

Luca Flesia ^{1,*}, Valentina Fietta ², Carlo Foresta ¹ and Merylin Monaro ²

"Evidence shows that differences in motivations for installing the apps are associated with differences in behavioral patterns."

- Flesia et al. 2021: Individuals using apps with the primary aim of finding friends were less likely to smoke or alcohol than other app users.
- "App user" is not precise enough.



Flesia, Luca, Valentina Fietta, Carlo Foresta, and Merylin Monaro. 2021a. Cigarette Smoking and Dating App Use: Findings from a Survey in a Sample of Adults in Italy. European Journal of Investigation in Health, Psychology and Education 11: 557–69.

Flesia, Luca, Valentina Fietta, Carlo Foresta, and Merylin Monaro. 2021b. The Association between Dating Apps and Alcohol Consumption in an Italian Sample of Active Users, Former Users, and Non-Users. Social Sciences 10: 249.



Cross-sectional study using NIH National Surveys on Drug Use and Health (NSDUH) **2015-2019**, & National Vital Statistics System Multiple Causes of Death files **2015-2019**, which looked at **195,711** respondents:

- Over 14.7 million people (5.4 percent of the population) have tried methamphetamine at least once.
- **OD death 1 180%** (5,526 \rightarrow 15,489)
- Use 1 43% (1.4 million \rightarrow 2.0 million)
 - Frequent use **1** 66% (615,000 \rightarrow 1,021,000)
 - Prevalence of MUD or injection surpassed the prevalence of methamphetamine use without MUD or injection since 2017 (60% to 67% vs 37% to 40%, 2017-2019)









Cross-sectional study using NIH National Surveys on Drug Use and Health (NSDUH) **2015-2019**, & National Vital Statistics System Multiple Causes of Death files **2015-2019**, which looked at **195,711** respondents:

- \Rightarrow 3x increase adjusted prevalence of MUD among heterosexual women (from 0.24% to 0.74%) and lesbian or bisexual women (from 0.21% to 0.71%).
- > 2x increase adjusted prevalence of MUD among heterosexual men (from 0.29% to 0.79%) and gay or bisexual men (from 0.29% to 0.80%)
- 10x increase among Black individuals (from 0.06% to 0.64%; P < .001), nearly tripled among White individuals (from 0.28% to 0.78%; P < .001),







Cross-sectional study using NIH National Surveys on Drug Use and Health (NSDUH) **2015-2019**, & National Vital Statistics System Multiple Causes of Death files **2015-2019**, which looked at **195,711** respondents:

- Risk factors for methamphetamine use, MUD, injection, and frequent use:
 - Iower educational attainment
 - Iower annual household income
 - □ lack of insurance
 - housing instability
 - criminal justice involvement
 - comorbidities (eg, HIV/AIDS, hepatitis B or C virus, depression)
 - suicidal ideation, and



- polysubstance use
 - Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. JAMA Psychiatry. 2021 Dec 1;78(12):1329-1342. doi: 10.1001/jamapsychiatry.2021.2588. PMID: 34550301; PMCID: PMC8459304.





Cross-sectional study using National Surveys on Drug Use and Health (NSDUH) 2015-2019, & National Vital Statistics System Multiple Causes of Death files 2015-2019, which looked at **195,711** respondents:

Who is Not Covered by NSDUH?

- Children under age 12
- Populations with potential serious mental health/substance use issues:
 - Institutionalized populations:
 - » Incarcerated
 - » Hospitalized
 - » Nursing homes
 - Homeless populations not in homeless shelters





Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. JAMA Psychiatry. 2021 Dec 1;78(12):1329-1342. doi: 10.1001/jamapsychiatry.2021.2588. PMID: 34550301; PMCID: PMC8459304

SAMHSA

2018 Methamphetamine Laboratory Incidents EPIC's Top 10







The National Clandestine Laboratory Seizure system compiled by the Missouri State Highway Patrol

American Academy of Addiction Psychiatry

- Euphoria
- Grandiosity
- Enhanced energy
- Alertness
- Suppression of appetite,
- Sexual stimulation
- Sociability

- Dysphoria
- Anxiety
- Restlessness
- Stereotypic behavior
- Psychomotor agitation
- Impaired judgement
- Psychosis
- Vomiting, Seizure, Delirium







- \uparrow Dopamine D1 activation \rightarrow reward pathway
- \uparrow Norepinephrine \rightarrow increase arousal, cardiovascular and stress pathway
- \uparrow Serotonin \rightarrow elevates mood



- A Glutamate: development of sensitization and craving
- ↑ GABA: attenuates reinforcement from stimulants and response to drug cues
- ↑ Acetylcholine: improves sustained attention
- ↑ Oxytocin: increase sociability
- ↑ CRF: activates stress pathways that facilitate drug seeking and relapse
- \Rightarrow TLR4 activation on microglia modulate the reinforcing effect of stimulants



Incentive sensitization theory

- An attempt to explain the increase of craving despite reduce euphoric effect
- It theorized addiction as excessive amplification specifically of psychological 'wanting', especially triggered by cues, without necessarily an amplification of 'liking' (mediate by dopamine).
 - Prolonged stimulant use \rightarrow Sensitization of dopamine and glutamate neurons in the mesolimbic system to drug-related cues
- Dopamine knockout mice still likes sugar, separating "liking" and "wanting"



Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol. 2016 Nov;71(8):670-679. doi: 10.1037/amp0000059. PMID: 27977239; PMCID: PMC5171207.

-Caffeine: inhibitor at the adenosine receptors

- -Cocaine: dopamine transporter protein blockade->increased **dopamine** at the synaptic cleft
- -Methamphetamine: increases release of norepinephrine, dopamine, and serotonin
- -Amphetamines: catecholamine induction, particularly norepinephrine and **dopamine**
- -Modafinil: dopamine uptake inhibitor, specifics unclear
- -Methylphenidate: blocks **dopamine** transporter (DAT) and norepinephrine transporter (NET) ->increased dopamine and norepinephrine levels and decreased reuptake
- -Nicotine: nicotinic agonist at nicotinic acetylcholine receptors, also stimulates the **dopaminergic** system
- -Ephedrine (e.g., ma huang): increased norepinephrine activity
- -Pseudoephedrine: increased norepinephrine activity
- -True cathinones (e.g., khat): keto-amphetamine, increase **dopamine** release and inhibited reuptake of epinephrine, norepinephrine, and serotonin



Synthetic cathinones (e.g., bupropion, "bath salts"): similar to true cathinones

Screening for Methamphetamine Use



- 1. Physical Exam Findings
 - a. Weight loss
 - b. Dental caries
 - c. Skin picking lesions
 - d. Teeth grinding/jaw clenching
 - e. Track marks
- 2. Medical Consequences
 - a. Cardiomyopathy
 - b. Malignant Hypertension
 - c. Aortic Dissection
 - d. Arrhythmias
 - e. Coronary vasospasm
 - f. Stroke (hemorrhagic)
 - g. STIs





Methamphetamine 2016-2019



SAMHSA, The National Survey on Drug Use and Health: 2019, September 14, 2020.



Crystal, Sex, and Technology

The Perfect Storm

Sex, both virtual and real, both safe and unsafe, is only a click or a swipe away.

◆ Variable Intermittent Reinforcement



Dating Sites and Apps




The Social Network

Scruff, Grindr, GROWLr etc.
 Adam4Adam or just "A4A" or "Adam"
 OkCupid, Plenty of Fish, and Tinder
 Tumblr, Reddit etc. non-dating site



ENGLISH ESPAÑOL FRANÇAIS PORTUGUÊS DEUTSCH









5/17/2023:



Ju/droot

u/droopymangoes • 14h

NSFW

쓥 2 👮 1

 \leftarrow

TIFU by smoking meth for the first time last weekend

Q

2

D

I was talking to someone on Grindr after work Friday and they wanted to try something different. I was initially hesitant because this person seemed like they were into some high-risk stuff and didn't disclose their status without me inquiring about it. initially I said no and told them about the red flags. But I was thinking with my dick and not my head. Told myself I'm down to try new things so I went.

On my way home from work I turned the car around and drove to the location they sent me. I scoped out the perimeter and made my way into a parking spot. After keeping my wallet in the glove box, I got out of the car and walked up the stairs to the room. The door was unlocked, as agreed, and I walked into a dark room smelling of cheap cigarette smoke and the tv playing family guy. He was naked laying on the bed with a cigarette in his hand.

Slipping off my shoes and pants, I hopped onto the bed next to him. He insisted I take my shirt off too, to which I said no as I didn't want to stay very long. He started blowing me for a minute before stopping. He picked up his meth pipe, heated the bowl end, and blew a few mouthfuls of clouds. He asked if I wanted any and I said no. He continued back to blowing me again. I n planned to smoke meth. He took another break to smoke

1272 people are here



🙂 💷 🖓



COVID-19

"A massive increase [in traffic] of 18.5% occurred on March 24th [2020] when it was announced that Pornhub's Premium service would be free to all visitors worldwide for one month to encourage people to stay at home and help flatten the curve of new COVID-19 cases."

Cybersex: An All-Inclusive Term Online Pornography Online Dating Sex Chats Sex Webcams (w. Drug use?) Teledildonics



Levounis and Sherer, The Technological Addictions, American Psychiatric Publishing, 2021

Self-Medication of Excess Social Stress

Discrimination **Expectation or Perception of Discrimination** Internalized Homophobia ♦ Labels "Straight acting" Sense of belonging & empowerment \rightarrow wrapped sense of confidence Levounis PyDreschered, Barber ME, The LGBT Casebook, 2012.



Treatment

Group Psychotherapy

- Crystal Clear Joseph S. Ruggiero, PhD
- Individual Counseling
- Family Therapy
- Contingency Management (CM)
- Crystal Methamphetamine Anonymous
- Treatment of Co-occurring Disorders



Treatment

No FDA Approved medication for treatment of stimulant use disorders Promising Candidates:

- Topiramate
- Bupropion
- Naltrexone (with or without buprenorphine)
- Amphetamine/Methylphenidate
- Modafinil
- Disulfiram
- Mirtazapine



Treatment



Cocaine vaccine dAd5GNE - active research. Current hurdle: need high anti-cocaine antibody titers



Summary

-Excess stress is likely responsible for higher rates of use among LGBTQ people.

-Crystal meth is the turbo cocaine (higher dopamine spike, longer acting)

Internet and apps have revolutionized drugs and sex.

-Psychotherapy >> pharmacotherapy

-Cultural humility and sensitivity is key to prevention.



A case of severe gammahydroxybutyrate (GHB) withdrawal with hemodynamic lability and rhabdomyolysis



Cara Borelli, DO Addiction Medicine Yale School of Medicine

No financial interests or relationships to disclose

Case presentation: history

-A 26-year-old male presented to the emergency department seeking treatment for GHB (gamma-hydroxybutyrate) withdrawal. He had a history of ADHD and opioid use disorder in sustained remission (past cardiac arrest from overdose).

-He reported using 3mL of GHB orally every hour including waking up at night to use GHB for the last 2.5 years.

-He reported smoking methamphetamine several times per day. He denied using any other substances including no alcohol.

-He had last used GHB and methamphetamine 2 hours prior to presentation in the emergency department.

-His symptoms included tremors, nausea, vomiting, and anxiety, which he had experienced during previous attempts at cessation of GHB.



Case presentation: physical examination

- The patient was awake, alert, and answering questions appropriately
- The physical examination was remarkable only for tachycardia and a mild tremor with his arms outstretched
- His heart rate upon presentation was 123 beats per minute, blood pressure was 156/98 mmHg, temperature 97.6°C, respiratory rate 20 breaths per minute, and oxygen saturation of 95% on room air.





Case presentation: emergency department workup and treatment

-The patient had a medical workup including an electrocardiogram significant only for sinus tachycardia and basic labs.

-He was found to have an elevated ALT (49 U/L) and AST (38 U/L).

-His white blood cell count and creatinine were within normal limits.

-His urine toxicology was positive for benzodiazepines and amphetamines.

-His serum ethanol level was undetectable.

-He was treated with intravenous fluids and diazepam 5 mg IV. With IV fluids and the diazepam as above, his heart rate trended down to 97 beats per minute. He was admitted to the inpatient detoxification unit.



The first 24 hours after last GHB use

-The patient's vital signs were within normal limits by the next morning, approximately 12 hours after his last use of GHB.

-The patient was started on a diazepam taper 10mg orally (scheduled for q4 hours) and received 2 doses, but further doses were not given initially due to concern that the patient was overly sedated in the morning with difficulty answering questions without falling asleep mid-sentence. Other than fatigue, the patient was answering questions appropriately and had no complaints.



The first 24 hours after last GHB use: fulminant withdrawal

-In the afternoon, 16 hours after the patient's last use of GHB, the patient's heart rate increased to 100 beats per minute, and he developed severe tremors in the extremities even with his arms not extended. The patient became confused, agitated, and developed paranoia that someone was waiting for him outside the door. The patient was treated with an additional 50 mg of Librium orally, 10 mg of diazepam orally, 2 mg of Ativan IM, and baclofen 10 mg q8 hours.

-Despite this treatment, the patient's heart rate and tremors worsened, with a maximum heart rate of 152 beats per minute at 24 hours after his last GHB use with a blood pressure of 147/95 mmHg. Further laboratory testing was ordered including creatine kinase due to concern for rhabdomyolysis, and his creatine kinase was found to be elevated at 6099 U/L with a normal serum creatinine, which was treated with IVF. The patient was started on diazepam IV 10 mg q15 minutes PRN.



24 to 48 hours after last GHB use: improving symptoms

-The patient was started on a 4-day chlordiazepoxide taper starting at 50mg q6 hours with continuation of the PRN diazepam orally and IV for withdrawal symptoms with a plan to escalate to phenobarbital and/or continuous infusions of dexmedetomidine, propofol, benzodiazepines and transfer to the ICU if needed.

-From hours 24 to 48 after his last GHB use, he received 200 mg of chlordiazepoxide, 3 doses of baclofen 10 mg, 50 mg of diazepam IV via PRN dosing, and 5 mg of diazepam orally via PRN dosing. He also received clonidine 0.1 mg and olanzapine 5 mg IV for agitation as well as thiamine, folate, and a multivitamin for nutritional support. He did not require phenobarbital or continuous intravenous infusions of sedatives.

-By the time of the assessment at 41 hours from his last GHB use, his vital signs had returned to within normal limits. -His laboratory testing showed down-trending creatine kinase and uptrending AST and ALT (70 and 46 IU respectively).

-The patient still had mild confusion and faint tremors in the extremities, but he was able to hold a conversation with the physician and answer most questions appropriately. The patient requested to go home to continue treatment as an outpatient but was encouraged to stay inpatient.



Case conclusion

- By day 7, the patient was no longer requiring benzodiazepines PRN. The patient expressed that he no longer wanted to take prescription benzodiazepines. He was informed that a longer-term benzodiazepine taper may be recommended and that he could follow up closely as an outpatient for arrangement for protracted benzodiazepine withdrawal symptoms. The patient was also offered long-term medications for protracted GHB withdrawal through the outpatient addiction institute. He declined inpatient rehabilitation and preferred to follow up as an outpatient. He was discharged with a plan for close addiction medicine follow-up and group therapy through the "Crystal Clear" group, a group for LGBT+ men with methamphetamine and other substance use.



One month phone follow-up

Reported symptoms	Patient quote
Fatigue	"I was at a meeting, and I just fell asleep. I'm mentally and physically exhausted."
Insomnia	"[Insomnia] is getting better."
Motor/coordination difficulties	"I just drop stuff [referencing a pen]. It just scares me."
Cognitive difficulties	"Processing information is difficult."
Retrograde amnesia	"I don't remember anything about those days [during his hospitalization]. I don't remember you [being his physician]. Apparently I was trying to convince my best friend to bring me drugs."

-The patient reported that overall his symptoms had been improving since discharge, and he had been attending self-help groups but had not followed up with our facility for medication management or therapy.



Gamma-hydroxybutyrate: a review

GHB biochemistry

-Gamma-hydroxybutyrate (GHB), or its precursors gamma-butyrolactone (GBL) and 1,4-Butanediol ("BDO"), is an endogenous compound that is a gamma aminobutyric acid (GABA) analog. It differs from GABA in that it has a hydroxyl group instead of the amino group on the GABA molecule.

-Endogenous GHB is synthesized from GABA, and GABA is synthesized from glutamate. GHB has significant first-pass metabolism via the liver. The Krebs cycle degrades most of GHB and forms of succinic semialdehyde and succinic acid. GHB is also in part metabolized to a much smaller degree via GABA transaminase into GABA. Thus, GHB is both a prodrug and metabolite of GABA.









GHB biochemistry

-Gamma-hydroxybutyrate (GHB), or its precursors gamma-butyrolactone (GBL) and 1,4-Butanediol ("BDO"), is an endogenous compound that is a gamma aminobutyric acid (GABA) analog. It differs from GABA in that it has a hydroxyl group instead of the amino group on the GABA molecule.

-Endogenous GHB is synthesized from GABA, and GABA is synthesized from glutamate. GHB has significant first-pass metabolism via the liver. The Krebs cycle degrades most of GHB and forms of succinic semialdehyde and succinic acid. GHB is also in part metabolized to a much smaller degree via GABA transaminase into GABA. Thus, GHB is both a prodrug and metabolite of GABA.







GHB biochemistry

-GHB binds with high affinity to GHB receptors (excitatory effect) and with weak affinity to GABA-B receptors. New research also shows that it may bind with high affinity to the $\alpha 4\beta \delta$ subtype of the GABA-A receptor (although conflicting evidence in studies).

-Endogenous levels of GHB do not have significant GABA-B receptor binding, and the effects are primarily on the GHB receptor, whereas exogenous high doses causes more GABA activation.

-Chronic exogenous GHB causes downregulation of GABA-B receptor and GHB receptor, but to a small or no extent downregulation of the GABA-A receptor.





GHB use



-Gamma-hydroxybutyrate (GHB) is clinically important both in overdose and withdrawal

-The time to reach peak plasma concentration is rapid, and **the elimination half life of 20-40 minutes**, which is why patients who overdose can have rapid improvement in symptoms (i.e., the classic GCS 3 to self-extubation transition). A dose-dependent mixed stimulant/sedative effect has been described, with stimulant and euphoric effects predominating early in the time course followed by the sedative effect.



-The amount ingested is usually measured in mL with a typical concentration of 1 g/mL, but the concentration varies making quantification difficult. Some people quantify in "eye droppers," e..g, 1 mL worth each).



GHB use

-GBL and BDO are **highly emetogenic** solvents that are also sold as industrial cleaners and come in liquid form (sometimes mixed with other drinks such as juice to reduce emesis), whereas GHB can be in salt or liquid form.

-**Pro-drugs can be taken directly or easily synthesized** into GHB, e.g., GBL + water + NaOH, which is an exothermic reaction.

-These used to available over-the-counter in vitamin stores and gyms

The 1990s, but increased regulation has led to online acquisition. TE.g., one patient bought GBL on Amazon several years ago.



GHB use



-Recreational GHB (aka "G," Gina, Liquid Ecstasy) has regional variations in use, with increased use noted in England, Ireland, and the Netherlands, as well as the United States in cities such New York City, San Francisco, and Miami particularly in nightclubs and parties by men who have sex with men due to its anxiolytic and strong euphoric effects, and sexualized drug use/"chemsex" with frequent co-ingestants in this population include alcohol and methamphetamine -For example, one patient described its effects as "alcohol, but it only lasts one hour without the hangover" and another "like the first time taking Adderall" -Other unprescribed uses: self-medication for insomnia, anxiety, and for bodybuilding (increases serum growth hormone even in the absence of sleep). It has also been used in sexual assault.

-Prescribed uses: GHB salt is available by prescription for narcolepsy, marketed as Xyrem or sodium oxybate (dual-scheduled I and III). It has also been used in Europe as a treatment for alcohol withdrawal.

GHB overdose: CNS and respiratory depression



-A dose-dependent mixed stimulant/sedative effect has been described, with stimulant and euphoric effects predominating early in the time course followed by the sedative effect. Co-ingestants such as **alcohol or benzodiazepines can increase sedation**.

-The time to reach peak plasma concentration is rapid, and the typical **elimination half life is less than 60 minutes**, which is why patients who overdose can have rapid improvement in symptoms (i.e., the classic GCS 3 to self-extubation transition). Activated charcoal is not recommended due to rapid absorption of GHB.

-GHB testing is frequently via a send-out lab, and it takes around 7 days to result.

-Treatment is supportive care with close monitoring of respiratory status. Based on clinical evaluation, consider EtOH, glucose, APAP, ASA level, EKG, CT head. Don't anchor! Consider screening for assault (sexual or physical).

Monitor for symptoms of GHB withdrawal

GHB use disorder and withdrawal



-Due to its short half-life, users who develop a substance use disorder develop use multiple times per day, often waking up at night to ingest more GHB, and am inability stop GHB due to withdrawal symptoms.

-Severe withdrawal is associated with **frequent ingestion** every 1 to 3 hours (e.g., one patient set a timer to re-dose every one hour and 35 minutes) and **waking up at night to ingest more**.

-Withdrawal symptoms include anxiety, tremor, tachycardia, vomiting, diaphoresis, and insomnia.

-In severe withdrawal patients sometimes experience initial improvement and then a precipitous worsening of symptoms that can mimic delirium tremens. Severe symptoms include **severe agitation, seizures, hallucinations, and delirium**. Vital sign derangements can include hypertension and tachycardia but are not typically as profound as when seen in delirium tremens. Rhabdomyolysis, renal failure, seizures, and death have been described from severe GHB withdrawal.

The acute withdrawal duration is variable with ranges typically from 2 to 15 days.

GHB withdrawal: acute phase

-There are no randomized controlled trials of treatment of GHB withdrawal, but treatment by front-loading benzodiazepines such as diazepam both orally and intravenously is the most common approach.

-Additionally, gabapentin, propofol, dexmedetomidine, and phenobarbital for refractory withdrawal have been described (phenobarbital binds directly to the ion channel and can function without the GABA-A receptors alpha subunit). A treatment pathway identical to the treatment pathway for severe alcohol withdrawal can be used; e.g., front-loading with benzodiazepines and escalating to phenobarbital and then dexmedetomidine.

-Baclofen, due to its affinity for the GABA-B receptor, has also been described both as an adjunct for severe withdrawal or as a monotherapy for withdrawal. Baclofen is typically started at 10 to 25 mg TID and can be escalated. One case report started at 30 mg upfront and escalated to scheduled doses of 20–40 mg every 4 hours in addition to PRN doses of 20–40 mg q4h orally and then tapered over the course of 7 days.

-A taper of pharmaceutical GHB is routinely used in the Netherlands.

-Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scoring is sometimes used for monitoring withdrawal and treatment, but it has not been validated for GHB withdrawal.

-There is anecdotal evidence that some people self-medicate with phenibut during withdrawal for similar GABA-B receptor effect, which unfortunately has its own withdrawal risk.

-Other non-medically-supervised strategies described online on drug forums such as Erowid and Bluelight include a self-taper of GHB, use of non-prescribed benzodiazepines, or pregabalin/gabapentin.

Possible mechanisms of withdrawal symptoms

Table 2. Possible neurological explanations for GHB withdrawal symptoms and signs

Withdrawal symptom	Possible main neurotransmitter effect
Auditory/visual hallucinations, paranoia	+ Dopamine
Tremors	+ Acetylcholine, serotonin
Tachycardia/palpitations	+ Acetylcholine, + noradrenaline
Hypertension	+ Noradrenaline
Sweating/hyperthermia	+ Dopamine, + noradrenaline, - serotonin
Anxiety	- GABA, + glutamate, - neurosteroids, fluctuating serotonin
Agitation/aggression	+ Serotonin, + glutamate
Pain	- Opioids
Insomnia/sleeping disorder	– GABA, + dopamine
Disorientation/delirium	+ Dopamine, + noradrenaline , – GABA
Depressive reaction	– Serotonin, – neurosteroids, GABA
Hypothermia/hyperthermia	+ Dopamine
Muscle contractions/convulsions	+ Acetylcholine, – GABA

+ = Increase; - = decrease/inhibition.

GHB withdrawal: protracted withdrawal

-This patient's persistent but improving symptoms one month after inpatient detoxification could be secondary to GHB withdrawal with components of protracted benzodiazepine and methamphetamine withdrawal.

-Protracted withdrawal symptoms from GHB may occur lasting 3-6 months following detoxification including impaired cognition and memory, anxiety, depression, tremor, severe insomnia, and motor symptoms possibly due to direct neurotoxicity.

-Baclofen due to its GABA-B mechanism is sometimes prescribed for protracted GHB withdrawal, but it has the potential for misuse. It is typically weaned over weeks as an outpatient if it is used for protracted GHB withdrawal.

-GHB use disorder has a high relapse rate of 60% within three month following detoxification. Close outpatient monitoring after detoxification is recommended with:

- -therapy including group or individual therapy
- -medical management of protracted withdrawal symptoms

-treatment underlying conditions such as insomnia or anxiety



Practice Questions



Practice questions

A 33-year-old male with a history of GHB use disorder presents in acute withdrawal with a heart rate of 125 and a blood pressure of 134/96. His last use was 2 hours prior, and he has been using 3 mL of GBL every 2 hours. He has a history of requiring an ICU stay in the past for GHB withdrawal. What do you use to treat him as a first-line? What adjuncts would you consider?



Key points

-Both GHB overdose and GHB withdrawal can be life-threatening.

-Patients who ingest GHB frequently throughout the day or wake at night to ingest more are at high risk for severe withdrawal.

-GHB withdrawal has clinical similarities to alcohol withdrawal. Severe agitation, seizures, hallucinations, and delirium can occur in severe withdrawal.

-GHB withdrawal is typically treated with benzodiazepines such as diazepam, but medications used in alcohol withdrawal treatment have been described including phenobarbital. Baclofen, a GABA-B receptor agonist, can be added as an adjunct or has been used as a monotherapy.

-Protracted withdrawal is common lasting three to six months, and baclofen has been used to treat cravings and relapse prevention. Close outpatient monitoring is recommended.

-There have not been studies on medications for alcohol use disorder such as camprosate or gabapentin for cravings or relapse-prevention for GHB.
Works Cited

1. Bourne A, Reid D, Hickson F, Torres Rueda S, Weatherburn P. The Chemsex Study: drug use in sexual settings among gay and bisexual men in Lambeth, Southwark and Lewisham. London: Sigma Research, London School of Hygiene and Tropical Medicine; 2014.

2. Pappas MK, Halkitis PN. Sexual risk taking and club drug use across three age cohorts of HIV-positive gay and bisexual men in New York City. AIDS Care. 2011;23(11):1410–6.

3. Theodore PS, Durán RE, Antoni MH. Drug use and sexual risk among gay and bisexual men who frequent party venues. AIDS Behav. 2014;18:2178–86.

Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med. 2001 Feb;37(2):147-53. doi: 10.1067/mem.2001.112985. PMID: 11174231.
 Freeman G, Siefried KJ, Roberts DM, Rodgers C, Nic Ionmhain U, Ramanathan J, Ezard N, Brett J. Phenobarbital to manage severe gamma-hydroxybutyrate withdrawal: A case series. Drug Alcohol Rev. 2023 Jan;42(1):27-32. doi: 10.1111/dar.13556. Epub 2022 Oct 21. PMID: 36269081.

Dijkstra BA, Kamal R, van Noorden MS, de Haan H, Loonen AJ, De Jong CA. Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: The Dutch GHB monitor project. Drug Alcohol Depend. 2017 Jan 1;170:164-173. doi: 10.1016/j.drugalcdep.2016.11.014. Epub 2016 Nov 21. PMID: 27923198.
 Kamal RM, van Noorden MS, Wannet W, et al. Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention. CNS Drugs. 2017 Jan;31(1):51-64. DOI: 10.1007/s40263-016-0402-z. PMID: 28004314.

8. Snead OC 3rd, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med. 2005 Jun 30;352(26):2721-32. doi: 10.1056/NEJMra044047. Erratum in: N Engl J Med. 2006 Feb 2;354(5):537. PMID: 15987921.

9. Pedraza C, García FB, Navarro JF. Neurotoxic effects induced by gammahydroxybutyric acid (GHB) in male rats. Int J Neuropsychopharmacol. 2009 Oct;12(9):1165-77. doi: 10.1017/S1461145709000157. Epub 2009 Mar 17. PMID: 19288974.

10. Dijkstra BAG, Beurmanjer H, Goudriaan AE, Schellekens AFA, Joosten EAG. Unity in diversity: A systematic review on the GHB using population. The International Journal on Drug Policy. 2021 Aug;94:103230. DOI: 10.1016/j.drugpo.2021.103230. PMID: 33892279.

11. Palamar JJ. Prevalence and Correlates of GHB Use among Adults in the United States. Journal of Psychoactive Drugs. 2022 May:1-6. DOI: 10.1080/02791072.2022.2081948. PMID: 35616605.

12. Tay E, Lo WKW, Murnion B. Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse. Subst Abuse Rehabil. 2022;13:13-23

13. Habibian S, Ahamad K, McLean M, Socias ME. Successful Management of Gamma-hydroxybutyrate (GHB) Withdrawal Using Baclofen as a Standalone Therapy: A Case Report. J Addict Med. 2019 Sep/Oct;13(5):415-417. doi: 10.1097/ADM.0000000000000514. PMID: 30907765; PMCID: PMC6752984.



Harm Reduction in Sexualized Substance Use



Alyssa Cheng, DO Slides courtesy of Jenna Butner, MD, MPH Addiction Medicine Yale School of Medicine

Case presentation: history

Sam, transgender female, age 28, engages in sexualized drug use ("chemsex") on weekends:

- Primary substances: methamphetamine and GHB
- Multiple sexual partners: cisgendered males, occasionally transgender females
- Inconsistent condom use
- Reports feeling invincible when using substances
- Difficulty negotiating safer sex practices when intoxicated



Key Risk Factors

Behavioral

- Decreased inhibition leading to higher-risk sexual practices
- Impaired decision-making
- Extended sexual sessions increasing tissue damage risk
- Multiple partners in group settings

Physiological

- Increased blood pressure and heart rate
- Dehydration
- Tissue inflammation and micro-abrasions
- Compromised immune system





Evidence-based Harm Reduction Strategies

STI Prevention Measures

- Regular HIV/STI screening (every 3 months)
- PrEP (Pre-Exposure Prophylaxis) for HIV prevention
- Readily available condoms and lubricants
- Dental dams and other barrier methods
- Post-exposure prophylaxis (PEP) awareness

Substance Use Safety

- Drug checking services
- Measured dosing
- Hydration monitoring
- Recovery periods between sessions
- Safe injection and inhalation practices if applicable

Community-Based Interventions

- Non-judgmental healthcare services
- Peer support programs
- Mobile testing units at relevant venues
- Educational resources in appropriate settings
- Crisis intervention services



Case presentation #2

Adrian, cisgender male, age 34 who works in high-stress corporate environment, attends weekend circuit parties

- Primary substances: MDMA, ketamine, cocaine, alcohol
- Sexual partners: cisgender males, uses condoms, takes sildenafil
- Reports increasing frequency of use over the last few months
- No regular primary care provider due to concerns over anonymity and stigma



Key Risk Factors

- Multiple substances used without drug checking
- Combining erectile dysfunction medications with stimulants
- Extended party sessions (48-72 hours)
- Irregular eating and sleeping patterns
- Avoiding medical and mental health care
- Large group settings with unknown participants
- Limited support system
- Financial strain
- Work performance concerns





Evidence-based Harm Reduction Strategies

Venue Safety

- Trusted location with proper ventilation
- Access to sterile water and electrolyte drinks
- Clear exits and emergency contacts visible
- First aid supplies readily available
- Cool-down spaces for rest periods

Personal Protection Kit

- Sterile drug paraphernalia
- Various barrier protection options
- Personal lubricants (water and silicone-based)
- Basic first aid items
- Emergency contact information
- Naloxone kit

Preparation

- Supply of various protection barriers
- PrEP adherence if prescribed
- Sterile/clean sex toys and proper cleaning supplies
- Personal hygiene supplies

Consent and Communication

- Pre-session boundary discussion
- Regular check-ins during sessions
- Established safe words/signals
- Clear communication about protection preferences
- Plan for handling consent violations



Community Resources and Digital Tools

Healthcare Access

- LGBTQ+ centered healthcare providers
- Specialized sexual health clinics
- Substance use treatment
- Mental health professionals
- Emergency medical services

Peer Support

- Community outreach programs
- Harm reduction organizations
- Support groups
- Online communities
- Educational workshops

Digital Tools

- Drug interaction checking apps
- Dose timing applications
- Emergency contact apps
- Health monitoring tools
- Location sharing with trusted contacts

Online Resources

- Reliable drug information websites
- Sexual health educational platforms
- Community forums
- Crisis hotline information
- Local resource directories



Case presentation #3



32-year-old male presented to the ED with severe methemoglobinemia (oxygen saturation 75%) after recreational use of Super RUSH.

Symptoms: cyanosis, dizziness, and tachycardia.

Treatment: methylene blue IV, O2 NC, monitoring

- I. How would you counsel the patient on preventing this in the future?II. Why would it be important to assess
- II. Why would it be important to assess exposure pattern: acute versus chronic long-term use?



Harm Reduction Practices: "Poppers"



A single mistake can prove fatal. We continue to receive reports of people dying or being severely injured after consuming poppers that resemble, and often mistaken for, popular energy shots. Drinking or inhaling poppers seriously jeopardizes your health. fda.gov/consumers/cons...



- Route: Inhalation only, from safe distance (never swallow or ingest).
- Use well ventilated areas
- Avoid: PD-5 Inhibitors, alcohol
- Product safety: sealed, check for signs of degradation (brown, strong smell)
- Usage: space out to allow recovery, small amounts, use with someone else

Rapid-fire multiple choice questions



Which of the following is FDA-approved for stimulant use disorder?

- A. mirtazapine
- B. topiramate
- C. methylphenidate
- D. bupropion
- E. none of the above



Which of the following is NOT a common substances used in chemsex and sexualized drug use?

- A. GHB
- B. methamphetamine
- C. ketamine
- D. anabolic steroids
- E. mephedrone
- F. MDMA



Which of the following is colloquially known as "poppers"?A.Nitrous oxideB.Alkyl nitritesC.MephedroneD.MethamphetamineE.MDMA



Withdrawal from which of the following can appear similar to alcohol withdrawal (tremors, tachycardia, agitation, seizures, etc.)?

- A. GHB
- B. methamphetamine
- C. ketamine
- D. mephedrone



Which of the following receptors may GHB bind to?
A. GABA-A
B. GABA-B
C. GHB
D. All of the charge

D. All of the above



Which of the following has evidence toward use for relapse prevention for GHB use disorder?

- A.Naltrexone
- B.Acamprosate
- C.Baclofen
- D.Diazepam



Final Takeaways/Summary

-The landscape of chemsex and sexualized drug use is changing in the information age, and in patients seeking treatment this should be explored

-Both GHB overdose and GHB withdrawal can be life-threatening

-Baclofen can be added as an adjunct or has been used as a monotherapy for GHB withdrawal as well as for relapse-prevention

-Harm reduction key principles:

STI/HIV screening

Knowledge of prevention: PrEP, PEP, condoms and lubricants

Usage methods mitigating unintended outcomes

Peer support, digital tools, LGBTQ-specialized treatment programs